10-K: Keros Therapeutics Announces 2024 Financial Results and Provides Business Update

Keros Therapeutics reports its 2024 financial results, highlighting key clinical program advancements and a new licensing agreement with Takeda Pharmaceuticals.

Summary

• Keros Therapeutics, Inc. reported a net loss of $187.4 million for the year ended December 31, 2024, and $153.0 million for the year ended December 31, 2023.
• The company's cash and cash equivalents totaled $559.9 million as of December 31, 2024.
• Existing cash, cash equivalents, and a $200 million upfront payment from Takeda are expected to fund operations into 2029.
• A global, multicenter, double-blind, randomized, placebo-controlled Phase 3 clinical trial to evaluate the efficacy and safety of elritercept versus placebo in patients with transfusion-dependent anemia with lower-risk MDS was initiated in December 2024.
• The company expects to present topline data from its Phase 2 clinical trial evaluating cibotercept in patients with PAH in the second quarter of 2025.
• Initial data from the Phase 1 clinical trial of KER-065 in healthy volunteers is expected in the first quarter of 2025.
• In December 2024, Keros entered into an exclusive license agreement with Takeda for elritercept, receiving a $200 million upfront payment and potential future milestones and royalties.

Sentiment

Score: 7

Explanation: The document presents a mix of positive and negative information. The Takeda deal and progress in clinical trials are positive, but ongoing losses and the termination of the TROPOS trial temper the overall sentiment.

Positives

• The company has a strong cash position of $559.9 million as of December 31, 2024.
• The Takeda licensing agreement provides a significant upfront payment of $200 million and potential future revenue streams.
• Clinical trials for elritercept, cibotercept, and KER-065 are progressing, with data readouts expected in 2025.
• The company has a proprietary discovery approach and knowledge base to develop new therapeutics.

Negatives

• The company has incurred net losses in every year since its inception and anticipates continuing to incur net losses in the future.
• The early termination of the TROPOS trial due to pericardial effusion adverse events is a setback for the cibotercept program.
• The company is dependent on the success of its product candidates, which are in clinical development, and faces significant competition from other biotechnology and pharmaceutical companies.

Risks

• The company will need substantial additional funding to complete the development and commence commercialization of its product candidates.
• Clinical trials are difficult to design and implement, and they involve a lengthy and expensive process with uncertain outcomes.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company's success depends in part on its ability to protect its intellectual property.
• The company relies on third parties to supply and manufacture its product candidates, and the development and commercialization of any products could be stopped or delayed if any such third party fails to provide sufficient quantities of product candidates or fails to do so at acceptable quality levels or prices.

Future Outlook

Keros expects its existing cash and cash equivalents, together with the $200 million upfront payment from Takeda, will be sufficient to fund its projected liquidity requirements into 2029.

Management Comments

• Jasbir S. Seehra, Ph.D., Chair and Chief Executive Officer of Keros, stated that the agreement with Takeda validates Keros' position as a leader in understanding the role of the TGFfamily of proteins.
• Chris Rovaldi, President and Chief Operating Officer of Keros, stated that Takeda is an ideal partner to maximize the potential of elritercept and that the upfront payment will enable Keros to extend its operational runway and advance cibotercept and KER-065.
• P.K. Morrow, Head of the Oncology Therapeutic Area Unit at Takeda, stated that Takeda is excited to partner with Keros and looks forward to exploring elritercept's potential and delivering it to patients with hematologic disorders.

Industry Context

The announcement highlights the increasing interest and investment in TGF-beta biology for therapeutic development, particularly in hematologic disorders and pulmonary arterial hypertension, with Keros positioning itself as a key player in this field.

Comparison to Industry Standards

• Merck's recent FDA approval of sotatercept (WINREVAIR) for PAH sets a high bar for efficacy in this indication, creating a competitive landscape for Keros' cibotercept.
• Sarepta's ELEVIDYS gene therapy approval for DMD provides a benchmark for innovative therapies in neuromuscular diseases, against which KER-065 will be evaluated.
• Bristol-Myers Squibb's Reblozyl and Geron Corporation's imetelstat (RYTELO) are established treatments for MDS-associated anemia, setting the standard for efficacy and safety that elritercept must meet or exceed.
• GSK's Ojjaara is an approved product for the treatment of intermediate or high-risk myelofibrosis in adults with anemia.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through successful development and commercialization of product candidates.
• Employees: Continued employment and potential for career growth within the company.
• Patients: Potential access to new and improved treatments for various diseases.
• Collaborators: Continued collaboration with Takeda and Hansoh to advance product development and commercialization.

Next Steps

• Present topline data from the Phase 2 clinical trial evaluating cibotercept in patients with PAH in the second quarter of 2025.
• Announce initial data from the ongoing Phase 1 clinical trial of KER-065 in a healthy volunteer adult population in the first quarter of 2025.
• Continue the Phase 3 clinical trial of elritercept in patients with lower-risk MDS.
• Evaluate the appropriate development strategy for cibotercept, including in PAH and other potential indications.

Key Dates

Keywords

elritercept, cibotercept, KER-065, Keros Therapeutics, Takeda, clinical trials, licensing agreement, financial results, TGF-beta, MDS, myelofibrosis, pulmonary arterial hypertension, neuromuscular diseases, cytopenias, anemia, thrombocytopenia, biopharmaceutical